Skip to main content

Generics

  • Mylan launches cabergoline tablets

    PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

    Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.

    Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.

     

  • Crossix Solutions offers new analytics tool to measure success of point-of-care campaigns

    NEW YORK — Crossix Solutions on Tuesday introduced its latest analytics innovation, Crossix POC Impact, which enables marketers to go beyond prescriber data and capture patient impact for a true representation of campaign effectiveness for the point-of-care marketing channel.

  • Generics to drive down HIV drug sales in next decade

    BURLINGTON, Mass. — The availability of new generic drugs for treating HIV will erode sales of HIV antiretroviral drugs into the next decade in developed countries, according to a new report.

    Healthcare market research firm Decision Resources released the report Wednesday, showing that sales of antiretroviral drugs in the United States, France, Germany, the United Kingdom, Spain, Italy and Japan would be $13.1 billion in 2022, down from 2012's $13.4 billion.

  • Reports: R.I. may set up prescription drug registry to combat abuse

    NEW YORK — Officials in Rhode Island may set up a registry that would allow doctors and pharmacists to track patients who have problems with drug abuse, according to published reports.

    The Associated Press reported that the proposed registry would track prescriptions for drugs that are controlled substance and allow healthcare professionals to track their usage, similar to a monitoring program set up in New York this year. A task force that includes state lawmakers, health officials and healthcare professionals met Monday to look at the idea.

  • Impax Labs to market generic or authorized generic version of OxyContin under deal with Purdue Pharma

    HAYWARD, Calif. — Impax Labs has settled a patent-infringement suit filed by Purdue Pharma concerning the opioid painkiller OxyContin, Impax said Tuesday.

  • CMS: Medicare Part D beneficiaries who hit 'doughnut hole' saved $8.9 billion in 2013 thanks to Affordable Care Act

    WASHINGTON — Elderly and disabled people nationwide have saved almost $9 billion on prescription drugs thanks to the Patient Protection and Affordable Care Act, according to a new study by the Centers for Medicare and Medicaid Services.

  • Roxane Labs' generic prostate drug gets tentative approval from FDA

    SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

    The FDA granted tentative approval to Roxane Labs' dutasteride capsules in the 0.5-mg strength. The drug is a generic version of GSK's Avodart, used to treat benign prostatic hyperplasia.

    Tentative approval means that a drug meets the agency's conditions for approval, but can't receive final approval until Avodart loses its patent protection, which will occur in 2015.

     

  • FDA gives tentative approval to Roxane pneumonia drug

    SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug for treating community-acquired pneumonia, agency records showed.

    According to the FDA's website, the agency granted the preliminary authorization for Roxane Labs' linezolid oral suspension in the 100-mg-per-5-mL strength.

X
This ad will auto-close in 10 seconds